SLN · Silence Therapeutics plc
$13.27
+0.10 (+0.76%)
At close · Aug 21
Market Cap
$824.78M
Shares
62.15M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$559K
-98.7%
FY2025
Net Income
-$88.61M
-95.6%
FY2025
Gross Margin
61.54%
-11.2pp
FY2025
Operating Margin
-16292.84%
-16146.5pp
FY2025
Diluted EPS
-$0.63
-90.9%
FY2025
Operating Cash Flow
-$62.27M
+7.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $615K | $559K | $43.26M | $31.64M | $21.66M | |
| $87K | $215K | $11.81M | $12.87M | $13.46M | |
| $528K | $344K | $31.45M | $18.78M | $8.19M | |
| — | 61.54% | 72.7% | 59.34% | 37.83% | |
| $47.56M | $67.75M | $67.88M | $56.94M | $43.55M | |
| $21.27M | $22.34M | $26.88M | $26.22M | $25.68M | |
| — | $1.32M | $0 | — | — | |
| -$68.31M | -$91.08M | -$63.32M | -$64.38M | -$61.04M | |
| — | -16292.84% | -146.38% | -203.47% | -281.87% | |
| -$59.95M | -$88.6M | -$44.46M | -$53.27M | -$49.65M | |
| $2000 | $11K | $845K | $956K | $688K | |
| -$59.95M | -$88.61M | -$45.31M | -$54.23M | -$50.33M | |
| — | -15851.88% | -104.74% | -171.37% | -232.44% | |
| -$61.89M | -$79.81M | -$46.36M | -$53.44M | -$50.42M | |
| USD/shares | — | -$0.63 | -$0.33 | -$0.49 | -$0.52 |
| USD/shares | — | -$0.63 | -$0.33 | -$0.49 | -$0.52 |
| shares | — | 141.69M | 138.75M | 111.28M | 96.58M |
| shares | — | 141.69M | 138.75M | 111.28M | 96.58M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.57×
EV/EBIT
—
Peer median 23.49×
P/E (TTM)
—
Peer median 13.64×
Peer medians compare against the 304 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| United Kingdom | $559,000 | $43,114,000 | $30,934,000 | $20,940,000 |
| Germany | — | $144,000 | $709,000 | $715,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research Collaboration Income | $559,000 | $43,114,000 | $30,933,000 | $20,940,000 |
| Royalty Income | $0 | $144,000 | $710,000 | $715,000 |
Key facts
CIK
1479615
CUSIP
82686Q101
13F (30d)
70 filings
70 filers
Visit website
Investor relations